83 related articles for article (PubMed ID: 23093354)
1. The PAR1 antagonist, SCH79797, alters platelet morphology and function independently of PARs.
Lee H; Hamilton JR
Thromb Haemost; 2013 Jan; 109(1):164-7. PubMed ID: 23093354
[No Abstract] [Full Text] [Related]
2. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
Wu CC; Teng CM
Eur J Pharmacol; 2006 Sep; 546(1-3):142-7. PubMed ID: 16890935
[TBL] [Abstract][Full Text] [Related]
3. Protease-activated receptor 1 antagonists prevent platelet aggregation and adhesion without affecting thrombin time.
Nadal-Wollbold F; Bocquet A; Bourbon T; Létienne R; Le Grand B
Eur J Pharmacol; 2010 Oct; 644(1-3):188-94. PubMed ID: 20655904
[TBL] [Abstract][Full Text] [Related]
4. Protease-activated receptor 1-selective antagonist SCH79797 inhibits cell proliferation and induces apoptosis by a protease-activated receptor 1-independent mechanism.
Di Serio C; Pellerito S; Duarte M; Massi D; Naldini A; Cirino G; Prudovsky I; Santucci M; Geppetti P; Marchionni N; Masotti G; Tarantini F
Basic Clin Pharmacol Toxicol; 2007 Jul; 101(1):63-9. PubMed ID: 17577318
[TBL] [Abstract][Full Text] [Related]
5. The contribution of thrombin-induced platelet activation to thrombus growth is diminished under pathological blood shear conditions.
Lee H; Sturgeon SA; Jackson SP; Hamilton JR
Thromb Haemost; 2012 Feb; 107(2):328-37. PubMed ID: 22187047
[TBL] [Abstract][Full Text] [Related]
6. Amyloid beta peptide-activated signal pathways in human platelets.
Shen MY; Hsiao G; Fong TH; Chen HM; Chou DS; Lin CH; Sheu JR; Hsu CY
Eur J Pharmacol; 2008 Jul; 588(2-3):259-66. PubMed ID: 18511035
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of proinflammatory cytokines by SCH79797, a selective protease-activated receptor 1 antagonist, protects rat kidney against ischemia-reperfusion injury.
El Eter EA; Aldrees A
Shock; 2012 Jun; 37(6):639-44. PubMed ID: 22592635
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin delays murine platelet activation in vivo even in the absence of endothelial NO synthase.
Ni R; Peleg T; Gross PL
Arterioscler Thromb Vasc Biol; 2012 Nov; 32(11):2609-15. PubMed ID: 22995523
[TBL] [Abstract][Full Text] [Related]
9. Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation.
Kuriyama S; Kashiwagi H; Yuhki K; Kojima F; Yamada T; Fujino T; Hara A; Takayama K; Maruyama T; Yoshida A; Narumiya S; Ushikubi F
Thromb Haemost; 2010 Oct; 104(4):796-803. PubMed ID: 20664890
[TBL] [Abstract][Full Text] [Related]
10. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
Bilodeau ML; Hamm HE
J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
[TBL] [Abstract][Full Text] [Related]
11. SCH79797 improves outcomes in experimental bacterial pneumonia by boosting neutrophil killing and direct antibiotic activity.
Gupta N; Liu R; Shin S; Sinha R; Pogliano J; Pogliano K; Griffin JH; Nizet V; Corriden R
J Antimicrob Chemother; 2018 Jun; 73(6):1586-1594. PubMed ID: 29514266
[TBL] [Abstract][Full Text] [Related]
12. Phosphoinositide 3-kinase induced activation and cytoskeletal translocation of protein kinase CK2 in protease activated receptor 1-stimulated platelets.
Nakanishi K; Toyoda H; Tanaka S; Yamamoto H; Komada Y; Gabazza EC; Hayashi T; Suzuki K; Ido M
Thromb Res; 2010 Dec; 126(6):511-6. PubMed ID: 21055793
[TBL] [Abstract][Full Text] [Related]
13. Preventing platelet thrombosis with a PAR1 pepducin.
Abdel-Latif A; Smyth SS
Circulation; 2012 Jul; 126(1):13-5. PubMed ID: 22705888
[No Abstract] [Full Text] [Related]
14. Synthesis and in vitro study of platelet antiaggregant activity of some 4-quinazolinone derivatives.
Gravier D; Dupin JP; Casadebaig F; Hou G; Boisseau M; Bernard H
Pharmazie; 1992 Feb; 47(2):91-4. PubMed ID: 1635928
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of resveratrol-induced platelet apoptosis.
Lin KH; Hsiao G; Shih CM; Chou DS; Sheu JR
Cardiovasc Res; 2009 Aug; 83(3):575-85. PubMed ID: 19423619
[TBL] [Abstract][Full Text] [Related]
16. YD-3, a novel inhibitor of protease-induced platelet activation.
Wu CC; Huang SW; Hwang TL; Kuo SC; Lee FY; Teng CM
Br J Pharmacol; 2000 Jul; 130(6):1289-96. PubMed ID: 10903968
[TBL] [Abstract][Full Text] [Related]
17. Discovery and synthesis of a novel series of quinoline-based thrombin receptor (PAR-1) antagonists.
Clasby MC; Chackalamannil S; Czarniecki M; Doller D; Eagen K; Greenlee WJ; Lin Y; Tsai H; Xia Y; Ahn HS; Agans-Fantuzzi J; Boykow G; Chintala M; Foster C; Bryant M; Lau J
Bioorg Med Chem Lett; 2006 Mar; 16(6):1544-8. PubMed ID: 16380251
[TBL] [Abstract][Full Text] [Related]
18. The mechanism of anti-platelet activity of davallialactone: involvement of intracellular calcium ions, extracellular signal-regulated kinase 2 and p38 mitogen-activated protein kinase.
Kim SD; Lee IK; Lee WM; Cho JY; Park HJ; Oh JW; Park SC; Kim SK; Kwak YS; Yun BS; Rhee MH
Eur J Pharmacol; 2008 Apr; 584(2-3):361-7. PubMed ID: 18313047
[TBL] [Abstract][Full Text] [Related]
19. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.
Serebruany VL; Kogushi M; Dastros-Pitei D; Flather M; Bhatt DL
Thromb Haemost; 2009 Jul; 102(1):111-9. PubMed ID: 19572075
[TBL] [Abstract][Full Text] [Related]
20. The platelet--thrombosis and beyond.
Langer HF; Weber C; Gawaz M
Thromb Haemost; 2013 Nov; 110(5):857-8. PubMed ID: 24108387
[No Abstract] [Full Text] [Related]
[Next] [New Search]
